Posted by Michael Wonder on 01 Aug 2018
Pfizer receives European approval for oncology biosimilar Trazimera (trastuzumab)
31 July 2018 - The European Commission decision marks the approval of Pfizer's first therapeutic oncology biosimilar.
Pfizer today announced the European Commission has approved Trazimera, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor over-expressing breast cancer and HER2 over-expressing metastatic gastric or gastro-esophageal junction adenocarcinoma.
This approval follows the recommendation from the Committee for Medicinal Products for Human Use in May 2018.
